The US Leader in Stem Cell Therapy, Now in Mexico. Treatments start at $3750 for 25 million stem cells!

Special Promo: Get an additional 25 BILLION Exosomes IV with treatments over 50 million cells!”

Price Match Guarantee
Schedule FREE Consult
Price Match Guarantee
Schedule FREE Consult

The US Leader in Stem Cell Therapy, Now in Mexico. Affordable treatments start at $3750 for 25 million stem cells!

Special Promo: Get an additional 25 BILLION Exosomes IV with treatments over 50 million cells!”

Menu

(888) 988-0515

What is Peripheral Blood Stem Cell Transplantation

Written by Dr. David Greene, MD, PhD, MBA on July 30, 2025

Table of Contents

Peripheral blood stem cell transplantation (PBSCT) is a treatment that restores healthy blood-forming stem cells after cancer therapy. To prepare, doctors give growth factor injections like Filgrastim, which move stem cells from the bone marrow into the bloodstream. These cells are then collected through apheresis, a procedure similar to a long blood donation. Once chemotherapy or radiation removes the damaged cells, the stored stem cells are infused back into the body through a simple IV. Inside the bone marrow, they begin producing new red blood cells, white blood cells, and platelets, helping the body recover.

Who Is Eligible

Patients typically must:

  • Be under ~70 years with good heart, lung, and kidney function.
  • Have chemo-sensitive blood cancer or marrow disorder.
  • Secure an HLA match—sibling, registry, or half-matched family (haplo).
  • Have no uncontrolled infection or severe organ damage.

Types of Transplant

Type

Source

Pros

Cons

Autologous

Your own cells

No GVHD risk, no donor needed

Possible cancer reinfusion

Allogeneic

Matched donor

Graft-versus-leukemia effect

GVHD risk, lifelong immunosuppression

Syngeneic

Identical twin

No rejection, no GVHD

Rare donor

Haploidentical

Half-matched

Widely available

Requires advanced GVHD control

2 | Global Growth in Numbers

Region / Year

Total Transplants

Blood-cell Graft Share

1998 worldwide

–

26% of allogeneic grafts

2022 United States

22 576 HCT

≈ 75% of unrelated donor cases

2022–23 China

39 918 HSCT

54% sibling, 77% haplo

The steady climb from one quarter of grafts in 1998 to three quarters in recent American data shows clear trust in the method. R3 Stem Cell Mexico follows these same global standards and tracks every case for quality.

Survival Rates & Outcomes

Disease

PBSCT 5-yr OS

Marrow 5-yr OS

Non-Hodgkin Lymphoma

52.7%

56.6%

Hodgkin Disease

52.7%

65.3%

Reduced-intensity haplo-AML (≥60 y)

42%

38%

Safety for Donors

Study of 1488 donations from 1994-98 recorded only 15 events linked to donation (1%) and zero deaths.

National Marrow Donor Program lists a 0.6 percent rate of serious events during collection.

  • Typical side effects include bone pain, mild headache, or fatigue. These effects soon after Filgrastim stops.

Such figures confirm the statement by Körbling and Anderlini that PBSCT “is the MOST common transplantation procedure in medicine”. At R3 Stem Cell Mexico every donor receives clear instructions, rapid lab checks, and round-the-clock support.

National Marrow Donor Program lists a 0.6 percent rate of serious events during collection.

Why Patients Recover Faster

  • Matched-pair study: neutrophils returned in 14 days with blood cells vs 19 days with marrow.
  • Large lymphoma review of 3,214 people showed quicker blood recovery across all disease groups.

Fast engraftment shortens hospital stay and lowers infection risk. This benefit is a key reason many oncologists now pick PBSCT first.

Balancing Benefits and Risks

Outcome area

Blood graft (PBSCT)

Bone-marrow graft

Neutrophil recovery (median)

14 days

19 days

Serious donor events

0.6 percent

≤0.5%

Chronic GVHD in aplastic anemia

Relative risk 1.80

Reference

Relapse in reduced-intensity AML age ≥60

Hazard ratio 0.65 (lower)

Reference

Numbers drawn from peer-reviewed trials and registries 1997-2024

  • Speed wins: faster white-cell return cuts time in isolation.
  • GVHD trade-off: higher chronic GVHD risk calls for close immune-suppressive care.
  • Lower relapse in some leukemias: older AML patients gain extra graft-versus-leukemia effect.

R3 Stem Cell Mexico weighs these factors with each patient and explains the plan in plain language.

Who Is Eligible

Step-by-Step Care Path

To give you a feel for how MSCs are used today, here’s where therapy is making waves:

Mobilize and collect

Growth factor shots move stem cells into the blood. Apheresis collects the cells while most blood returns to the donor. One or two sessions fit 85 percent of cases.

Condition

High-dose chemotherapy or radiation clears diseased marrow.

Infuse

Saved cells pass through a standard IV over four to six hours. Nurses watch heart rate and oxygen during the drip.

Engraft

Doctors track CD34+ count and daily blood tests until white cells hit at least 500 per microlitre.

Recover

Average hospital stay ranges from two to three weeks. Patients start daily walks and light meals once counts rise.

Common Early Side Effects

Symptom

Why it happens

Typical fix

Bone pain

G-CSF stimulates marrow

Short course of paracetamol or ibuprofen

Nausea / vomiting

Conditioning drugs

Antiemetic pills before meals

Mouth sores

Drop in white cells

Saline rinses, soft diet

Fatigue

Low red cells

Pack-cell transfusion if needed

R3 Stem Cell Mexico keeps a 24-hour hotline for any new fever, rash, or dizziness.

Long-Term Checks

  • Immune reset: childhood shots restart at month 3 to 6.
  • GVHD watch: skin, liver, and gut reviewed at each visit; rapid steroids if signs appear.
  • Organ health: yearly heart, lung, and kidney scans look for late toxicity.

Survival now equals that of marrow grafts in most cancers, yet quality of life hinges on timely GVHD control.

Special Cases: Radiation Injury

The 1999 Tokaimura criticality accident prompted doctors to give technician Hisashi Ouchi an experimental peripheral-blood stem-cell transplant from his sibling in an effort to restore his devastated marrow and immune system. The procedure temporarily raised his white-cell count, but it did not prevent progressive multiple-organ failure, and Ouchi died 83 days after the exposure. Although the attempt showed that peripheral stem-cell infusion could engraft in a patient with near-total marrow loss, it did not demonstrate proven clinical benefit in such extreme radiation injury cases.

Peripheral Blood Stem Cell Transplantation

Questions to Ask Your Team

  • Is my donor fully matched or half-matched?
  • Which conditioning drugs will you use?
  • How will you manage GVHD from day one?
  • When can I return to work or school?

Bring these points to your first consult at stemcellmexico.com.

Cost Facts and Insurance Tips

Main cost parts

  • Hospital stay
  • Growth factor shots like Filgrastim
  • Apheresis and lab work
  • Chemotherapy or radiation drugs
  • Follow-up visits and medicines to curb GVHD

Main cost parts

  • United States: often above 250,000 USD for an allogeneic case.
  • Mexico and many middle-income countries: nearly one third of that figure, based on published fee surveys and billing data from 2023.

Who pays what

Payer

What they may cover

Key notes

Public insurance (US Medicare, IMSS, others)

Most direct medical costs once the plan approves the transplant

Prior approval forms need lab proof of disease stage

Private insurance

Wide spread in coverage, check yearly cap

Many plans ask for an in-network center

Self pay

Full bill plus travel

Some centers offer package rates and payment plans

Save on hidden items

  • Ask if labs and imaging are bundled.
  • Confirm if growth factors are billed at cost or with a mark-up.
  • Check if the room fee includes meals for a caregiver.

Setting up Your Money Plan

  • Call your insurer and request a written list of covered codes.
  • Keep a binder for every bill. Dispute errors within thirty days.
  • Use charity flights or medical visas if you live far away.
  • Build an emergency fund equal to one month of lodging and food near the clinic.

Family and Caregiver Guide

Before admission

  • Freeze single-serve meals.
  • Arrange child or pet care for at least four weeks.

During hospital days

  • One visitor at a time keeps the infection risk low.
  • Bring a clean change of clothes and leave shoes at the door.

After discharge

  • Wipe kitchen and bath with bleach wipes each day.
  • Take the patient to lab visits twice each week until counts rise.
  • Call the team at once for fever above 100.4 °F or a new skin rash.

Life in the First Year

Time point

Common task

Goal

Week 1-3

Daily blood draws

Track engraftment

Month 1-3

Taper steroids if GVHD is stable

Cut infection risk

Month 3-6

Restart childhood shots

Rebuild immunity

Month 6-12

Return to part-time work or school

Restore routine

Regular light exercise, such as slow walks, helps fight fatigue. A diet rich in protein and iron speeds red cell growth. Avoid raw fish, unwashed fruit, and crowded events until your doctor clears them.

Research Trends to Watch

  • Busulfan plus cyclophosphamide remains the most used conditioning pair in China at 53 percent of cases, showing a global tilt toward busulfan-based plans.
  • New trials test post-transplant cyclophosphamide to drop chronic GVHD rates while keeping low relapse risk.
  • Gene editing studies aim to add tumor-killing traits to donor cells, early data look safe but need larger samples.

Key Takeaways

  • PBSCT now makes up about three-quarters of unrelated donor grafts in the United States and more than half in China.
  • Donor safety is high, with serious events around six in one thousand collections.
  • Recovery is quicker than with marrow harvest, yet chronic GVHD needs close watch.
  • Careful cost planning, clear insurance talks, and strong family help turn a complex treatment into a clear, step-by-step path back to health.

References

Wikipedia contributors. (2025a, July 13). Peripheral stem cell transplantation. Wikipedia. https://en.wikipedia.org/wiki/Peripheral_stem_cell_transplantation

Norooznezhad, A. H., Malek Mohammadi, A., Kamranzadeh Fumani, H., Aminian, P., Jalili, M., Nikbakht, M., Mousavi, S. A., Vaezi, M., Heshmati, F., Mohammadi, S., Alimoghaddam, K., & Ghavamzadeh, A. (2019). Peripheral blood stem cell apheresis in low-weight children: A single centre study. Transfusion and Apheresis Science, 58(3), 300–303. https://doi.org/10.1016/j.transci.2019.04.018

Lie, A. K., & To, L. B. (1997). Peripheral Blood Stem Cells: Transplantation and Beyond. The oncologist, 2(1), 40–49.

Körbling, M., & Freireich, E. J. (2011). Twenty-five years of peripheral blood stem cell transplantation. Blood, 117(24), 6411–6416. https://doi.org/10.1182/blood-2010-12-322214

Mishra, P. C., Seth, T., & Mahapatra, M. (2015). Peripheral blood stem cell transplant in aplastic anemia. Biology of Blood and Marrow Transplantation, 21(2), S38. https://doi.org/10.1016/j.bbmt.2014.11.031

Contact US

R3 Stem Cell Offers Financing Options 
For North American Residents, Wherever They Obtain Procedures!
US Patient Click Here
Canadian Patient Click Here

About R3 Stem Cell Mexico

R3 Stem Cell is a global leader in regenerative medicine, offering advanced stem cell and exosome therapies through Centers of Excellence in over 45 locations across 7 countries. Our mission is to provide first-rate, customized regenerative treatments, including stem cells, exosomes, PRP, vitamins, and peptides, to help patients achieve a better quality of life. With more than 26,000 procedures performed and an 85% patient satisfaction rate, our experienced, compassionate providers are committed to delivering safe, effective care. All therapies are nonsteroidal, outpatient procedures designed to harness the body’s natural repair mechanisms and support tissue regeneration. Individual results may vary, and only your medical professional can explain all the risks and potential benefits of any therapy based on your unique circumstances.
 

Follow Us

Instagram Facebook Youtube Twitter Linkedin

Quick Links

Menu

Disclaimer

Stem cell therapy is considered experimental and is regulated by the U.S. Food and Drug Administration (FDA), but it is not FDA-approved. R3 Stem Cell does not offer stem cell therapy as a cure for any medical condition. No statements made on this site have been evaluated or approved by the FDA. This site does not provide medical advice. All content is for informational purposes only and is not a substitute for professional medical consultation, diagnosis, or treatment. Reliance on any information provided by R3 Stem Cell, its employees, others appearing on this website at the invitation of R3 Stem Cell, or other visitors to the website is solely at your own risk. R3 Stem Cell does not recommend or endorse any specific tests, products, procedures, opinions, or other information that may be mentioned on this website. R3 Stem Cell is not responsible for the outcome of your procedure. The FDA considers stem cell therapy experimental at this point.

Contact Us

Copyright © 2016 – 2025 R3 Stem Cell

Refund Policy

Dr. David Greene

MD, PhD, MBA

Dr. David Greene, MD, PhD, MBA, is a pioneering leader in regenerative medicine and healthcare marketing. As a residency and fellowship-trained orthopedic surgeon, Dr. Greene transitioned from clinical practice to become the founder and CEO of R3 Stem Cell and US Lead Network, where he has revolutionized patient care and medical practice growth through innovative therapies and digital marketing strategies. He has authored two influential books on healthcare internet marketing, ranks among the top expert authors globally, and has been featured on the cover of Corporate Vision magazine for his impact on global regenerative therapies. Beyond his professional achievements, Dr. Greene is passionate about education, compassion, and continuous innovation. 

Full Bio
Twitter Youtube Instagram Facebook